Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia

Authors: Leonar Arroyo, Diana Marín, Kees L. M. C. Franken, Tom H. M. Ottenhoff, Luis F. Barrera

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Tuberculosis (TB) remains one of the most deadly infectious diseases. One-third to one-fourth of the human population is estimated to be infected with Mycobacterium tuberculosis (Mtb) without showing clinical symptoms, a condition called latent TB infection (LTBI). Diagnosis of Mtb infection is based on the immune response to a mixture of mycobacterial antigens (PPD) or to Mtb specific ESAT-6/CFP10 antigens (IGRA), highly expressed during the initial phase of infection. However, the immune response to PPD and IGRA antigens has a low power to discriminate between LTBI and PTB. The T-cell response to a group of so-called latency (DosR-regulon-encoded) and Resuscitation Promoting (Rpf) antigens of Mtb has been proved to be significantly higher in LTBI compared to active TB across many populations, suggesting their potential use as biomarkers to differentiate latent from active TB.

Methods

PBMCs from a group LTBI (n = 20) and pulmonary TB patients (PTB, n = 21) from an endemic community for TB of the city of Medellín, Colombia, were in vitro stimulated for 7 days with DosR- (Rv1737c, Rv2029c, and Rv2628), Rpf- (Rv0867c and Rv2389c), the recombinant fusion protein ESAT-6-CFP10 (E6-C10)-, or PPD-antigen. The induced IFNγ levels detectable in the supernatants of the antigen-stimulated cells were then used to calculate specificity and sensitivity in discriminating LTBI from PTB, using different statistical approaches.

Results

IFNγ production in response to DosR and Rpf antigens was significantly higher in LTBI compared to PTB. ROC curve analyses of IFNγ production allowed differentiation of LTBI from PTB with areas under the curve higher than 0.70. Furthermore, Multiple Correspondence Analysis (MCA) revealed that LTBI is associated with higher levels of IFNγ in response to the different antigens compared to PTB. Analysis based on decision trees showed that the IFNγ levels produced in response to Rv2029c was the leading variable that best-classified disease status. Finally, logistic regression analysis predicted that IFNγ produced by PBMCs in response to E6-C10, Rv2029c, Rv0867c (RpfA) and Rv2389c (RpfA) antigens correlates best with the probability of being latently infected.

Conclusions

The Mtb antigens E6-C10, Rv2029c (PfkB), Rv0867c (RpfA) and Rv2389c (RpfA), may be potential candidates to discriminate LTBI from PTB.
Appendix
Available only for authorised users
Literature
1.
WHO: Global tuberculosis report (WHO/HTM/TB/2016.13): World Health Organization. 2016.
2.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA. 1999;282(7):677–86.CrossRefPubMed
3.
Esmail H, Barry CE 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today. 2012;17(9–10):514–21.CrossRefPubMed
4.
Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–204.PubMed
5.
Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–104.CrossRefPubMed
6.
Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med. 2007;13(5):175–82.CrossRefPubMed
7.
Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium Bovis BCG and virulent M. Bovis. J Bacteriol. 1996;178(5):1274–82.CrossRefPubMedPubMedCentral
8.
Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284(5419):1520–3.CrossRefPubMed
9.
Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55.CrossRefPubMed
10.
Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J. 2016;48(6):1751–63.CrossRefPubMed
11.
Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. Inhibition of respiration by nitric oxide induces a mycobacterium tuberculosis dormancy program. J Exp Med. 2003;198(5):705–13.CrossRefPubMedPubMedCentral
12.
Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. Transcriptional adaptation of mycobacterium tuberculosis within macrophages: insights into the Phagosomal environment. J Exp Med. 2003;198(5):693–704.CrossRefPubMedPubMedCentral
13.
Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A. 2001;98(13):7534–9.CrossRefPubMedPubMedCentral
14.
Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002;43(3):717–31.CrossRefPubMed
15.
Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol. 2012;3:411.PubMed
16.
Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015;264(1):288–307.CrossRefPubMedPubMedCentral
17.
Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of mycobacterium tuberculosis. Mol Microbiol. 2003;48(3):833–43.CrossRefPubMedPubMedCentral
18.
Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB, Young M. A family of autocrine growth factors in mycobacterium tuberculosis. Mol Microbiol. 2002;46(3):623–35.CrossRefPubMed
19.
Shleeva MO, Bagramyan K, Telkov MV, Mukamolova GV, Young M, Kell DB, Kaprelyants AS. Formation and resuscitation of “non-culturable” cells of Rhodococcus rhodochrous and mycobacterium tuberculosis in prolonged stationary phase. Microbiology. 2002;148(Pt 5):1581–91.CrossRefPubMed
20.
Downing KJ, Mischenko VV, Shleeva MO, Young DI, Young M, Kaprelyants AS, Apt AS, Mizrahi V. Mutants of mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect Immun. 2005;73(5):3038–43.CrossRefPubMedPubMedCentral
21.
Kana BD, Gordhan BG, Downing KJ, Sung N, Vostroktunova G, Machowski EE, Tsenova L, Young M, Kaprelyants A, Kaplan G, et al. The resuscitation-promoting factors of mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol. 2008;67(3):672–84.CrossRefPubMed
22.
Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med. 2010;181(2):174–80.CrossRefPubMed
23.
Huang W, Qi Y, Diao Y, Yang F, Zha X, Ren C, Huang D, Franken KL, Ottenhoff TH, Wu Q, et al. Use of resuscitation-promoting factor proteins improves the sensitivity of culture-based tuberculosis testing in special samples. Am J Respir Crit Care Med. 2014;189(5):612–4.CrossRefPubMed
24.
Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of mycobacterium tuberculosis. Microbes Infect. 2006;8(8):2052–60.CrossRefPubMed
25.
Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KL, Friggen AH, Hill PC, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol. 2009;16(8):1203–12.CrossRefPubMedPubMedCentral
26.
Hozumi H, Tsujimura K, Yamamura Y, Seto S, Uchijima M, Nagata T, Miwa S, Hayakawa H, Fujisawa T, Hashimoto D, et al. Immunogenicity of dormancy-related antigens in individuals infected with mycobacterium tuberculosis in Japan. Int J Tuberc Lung Dis. 2013;17(6):818–24.CrossRefPubMed
27.
Araujo LS, da Silva NB, da Silva RJ, Leung JA, Mello FC, Saad MH. Profile of interferon-gamma response to latency-associated and novel in vivo expressed antigens in a cohort of subjects recently exposed to mycobacterium tuberculosis. Tuberculosis (Edinb). 2015;95(6):751–7.CrossRef
28.
Pena D, Rovetta AI, Hernandez Del Pino RE, Amiano NO, Pasquinelli V, Pellegrini JM, Tateosian NL, Rolandelli A, Gutierrez M, Musella RM, et al. A mycobacterium tuberculosis dormancy antigen differentiates latently infected bacillus Calmette-Guerin-vaccinated individuals. EBioMedicine. 2015;2(8):882–8.CrossRef
29.
Riano F, Arroyo L, Paris S, Rojas M, Friggen AH, van Meijgaarden KE, Franken KL, Ottenhoff TH, Garcia LF, Barrera LF. T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis (Edinb). 2012;92(2):148–59.CrossRef
30.
Arroyo L, Rojas M, Ortiz BL, Franken KL, Garcia LF, Ottenhoff TH, Barrera LF. Dynamics of the T cell response to mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis (Edinb). 2016;97:97–107.CrossRef
31.
Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol. 2011;41(10):2925–36.CrossRefPubMed
32.
Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, Angeletti C, Ottenhoff TH, Girardi E. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J. 2010;36(1):135–42.CrossRefPubMed
33.
Arroyo L, Rojas M, Franken KL, Ottenhoff TH, Barrera LF. Multifunctional T cell response to DosR and Rpf antigens is associated with protection in long-term mycobacterium tuberculosis-infected individuals in Colombia. Clin Vaccine Immunol. 2016;23(10):813–24.CrossRefPubMedPubMedCentral
34.
Huang W, Qi Y, Ren C, Wen H, Franken KL, Ottenhoff TH, Shen J. Interferon-gamma responses to mycobacterium tuberculosis Rpf proteins in contact investigation. Tuberculosis (Edinb). 2013;93(6):612–7.CrossRef
35.
Sutherland JS, Lalor MK, Black GF, Ambrose LR, Loxton AG, Chegou NN, Kassa D, Mihret A, Howe R, Mayanja-Kizza H, et al. Analysis of host responses to mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. PLoS One. 2013;8(9):e74080.CrossRefPubMedPubMedCentral
36.
Bai XJ, Liang Y, Yang YR, Feng JD, Luo ZP, Zhang JX, Wu XQ. Potential novel markers to discriminate between active and latent tuberculosis infection in Chinese individuals. Comp Immunol Microbiol Infect Dis. 2016;44:8–13.CrossRefPubMed
37.
Rakshit S, Adiga V, Nayak S, Sahoo PN, Sharma PK, van Meijgaarden KE, UJA UJ, Dhar C, Souza GD, Finak G, et al. Circulating mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis. Sci Rep. 2017;7(1):11948.CrossRefPubMedPubMedCentral
38.
del Corral H, Paris SC, Marin ND, Marin DM, Lopez L, Henao HM, Martinez T, Villa L, Barrera LF, Ortiz BL, et al. IFNgamma response to mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One. 2009;4(12):e8257.CrossRefPubMedPubMedCentral
39.
Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, Verduyn MJ, van Meijgaarden KE, Voskuil MI, Dockrell HM, et al. Lack of immune responses to mycobacterium tuberculosis DosR regulon proteins following Mycobacterium Bovis BCG vaccination. Infect Immun. 2007;75(7):3523–30.CrossRefPubMedPubMedCentral
40.
Franken KL, Hiemstra HS, van Meijgaarden KE, Subronto Y, den Hartigh J, Ottenhoff TH, Drijfhout JW. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif. 2000;18(1):95–9.CrossRefPubMed
41.
Cerda J, Cifuentes L. Using ROC curves in clinical investigation: theoretical and practical issues. Rev Chil Infectol. 2012;29(2):138–41.CrossRef
42.
Kass GV. An exploratory technique for investigating large quantities of categorical data. Appl Stat. 1980;29:119–27.CrossRef
43.
Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis. 2007;7(6):428–38.CrossRefPubMed
44.
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. Tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33(5):956–73.CrossRefPubMed
45.
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20.CrossRefPubMedPubMedCentral
46.
Le Roux BaR H. Geometric data analysis, from correspondence analysis to structured data analysis, Kluwer, Dordrecht. 1st ed. Netherlands: Springer; 2004.
47.
Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, Ottenhoff TH, Klein MR, Huygen K. Immunogenicity of eight dormancy regulon-encoded proteins of mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun. 2007;75(2):941–9.CrossRefPubMed
48.
Mensah GI, Addo KK, Tetteh JA, Sowah S, Loescher T, Geldmacher C, Jackson-Sillah D. Cytokine response to selected MTB antigens in Ghanaian TB patients, before and at 2 weeks of anti-TB therapy is characterized by high expression of IFN-γ and Granzyme B and inter-individual variation. BMC Infect Dis. 2014;14:495.CrossRefPubMedPubMedCentral
49.
Chegou NN, Black GF, Loxton AG, Stanley K, Essone PN, Klein MR, Parida SK, Kaufmann SH, Doherty TM, Friggen AH, et al. Potential of novel mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis. 2012;12:10.CrossRefPubMedPubMedCentral
50.
Gupta RK, Srivastava BS, Srivastava R. Comparative expression analysis of rpf-like genes of mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions. Microbiology. 2010;156(Pt 9):2714–22.CrossRefPubMed
51.
Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845–55.PubMedPubMedCentral
52.
Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol. 2009;17(5):183–8.CrossRefPubMed
53.
Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, et al. Human T cell responses to the ESAT-6 antigen from mycobacterium tuberculosis. J Infect Dis. 1999;179(3):637–45.CrossRefPubMed
54.
Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, North RJ. Expression levels of mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology. 2006;118:195–201.CrossRefPubMedPubMedCentral
55.
Cehovin A, Cliff JM, Hill PC, Brookes RH, Dockrell HM. Extended culture enhances sensitivity of a gamma interferon assay for latent mycobacterium tuberculosis infection. Clin Vaccine Immunol. 2007;14(6):796–8.CrossRefPubMedPubMedCentral
56.
Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT. Discrepancy between mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol. 2007;14(7):880–5.CrossRefPubMedPubMedCentral
57.
Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med. 2008;5(7):e145.CrossRefPubMedPubMedCentral
58.
Rueda CM, Marin ND, Garcia LF, Rojas M. Characterization of CD4 and CD8 T cells producing IFN-gamma in human latent and active tuberculosis. Tuberculosis (Edinb). 2010;90(6):346–53.CrossRef
59.
Marin ND, Paris SC, Rojas M, Garcia LF. Reduced frequency of memory T cells and increased Th17 responses in patients with active tuberculosis. Clin Vaccine Immunol. 2012;19(10):1667–76.CrossRefPubMedPubMedCentral
Metadata
Title
Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia
Authors
Leonar Arroyo
Diana Marín
Kees L. M. C. Franken
Tom H. M. Ottenhoff
Luis F. Barrera
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2929-0

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue

Research article

Distribution of virulence genes and their association with antimicrobial resistance among uropathogenic Escherichia coli isolates from Iranian patients

Research article

Dengue fever in Dar es Salaam, Tanzania: clinical features and outcome in populations of black and non-black racial category

Case report

Successful use of combined blood purification techniques in splenectomised patient with septic shock in streptococcus pneumoniae infection – a case report

Research article

Successful infection of BALB/c mice by a swine hepatitis E virus clone constructed with reverse genetics

Technical advance

Quality control implementation for universal characterization of DNA and RNA viruses in clinical respiratory samples using single metagenomic next-generation sequencing workflow

Case report

Severe diphtheria with neurologic and myocardial involvement in a Swedish patient: a case report

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits